Reference is made to the stock exchange announcement published by Nykode
Therapeutics ASA (the "Company") on 25 October 2023 regarding the successful
private placement of new shares (the "Private Placement"). 

Rasmussengruppen holds 36 030 750 shares in the Company on a consolidated basis
with Rasmussgruppen AS (30 180 750 shares), Portia AS (4 500 000 shares) and
Cressida AS (1 350 000 shares), equal to approximately 12.19% of the shares and
voting rights currently registered in the Norwegian Business Registry.

Neither of the above mentioned companies participated in the Private Placement
and upon registration of the share capital increase pertaining to the Private
Placement, Rasmussengruppen AS will individually cross the 10% threshold by
decreasing its holding of shares and votes in the Company from 10.21% to 9.29%.

On a consolidated basis, Rasmussengruppen will continue to hold a total of 36
030 750 shares and thereby decrease its consolidated holding from approximately
12.19% to 11.08% of the shares and voting rights in the Company.

The above mentioned companies consolidated with Rasmussengruppen have no other
rights to shares issued by the Company.

This announcement is made in accordance with Section 4-2 of the Norwegian
Securities Trading Act.